BioMark Diagnostics Inc. (CSE:BUX) is listed on the Canadian Securities Exchange in the Life Sciences sector, since November 3, 2014. The CSE has covered it in 3 stories since 2025.
CSE:BUXCompany profile on thecse.com
Also in these stories: FendX Technologies Inc. (CSE:FNDX), Metaguest.AI Incorporated (CSE:METG), Railtown AI Technologies Inc (CSE:RAIL), Sona Nanotech Inc. (CSE:SONA), Abound Energy Inc. (CSE:ABND), Avanti Gold Corp. (CSE:AGC)
January Highlights As 2025 comes to an end, we’re sharing our favourite highlights from another incredible year at the CSE. In January, we hit the ground running with a strong presence at VRIC, hosted our signature Mining Over Canada Reception, joined global financial market leaders on the slopes of the Italian Alps, and released our…
Abound Energy Inc. (CSE:ABND) and 83 more
Early detection is critical to improving survival rates and treatment outcomes for cancer patients, but traditional approaches such as mammograms, low-dose CT scans, and biopsies, while effective, come with challenges. High costs, accessibility, invasiveness, and the potential for false positives are some of the factors that can lead to delays in diagnosis or unnecessary treatments.…
BioMark Diagnostics Inc. (CSE:BUX)
Welcome to the latest issue of Canadian Securities Exchange Magazine, your source for in-depth stories of entrepreneurs from a wealth of different industries. Businesses are facing an operating landscape marked by mounting political tensions, rapidly shifting climate and trading realities around the world, and continuously evolving technology – particularly artificial intelligence (AI) – driving an…
BioMark Diagnostics Inc. (CSE:BUX) and 5 more
